Management strategy for follicular lymphoma

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Follicular lymphoma (FL) is an incurable B-cell malignancy.
• While survival has improved, optimal treatment strategies require refinement based on disease stage and tumor burden.
• Current approaches include watchful waiting, single-agent rituximab, and combination chemoimmunotherapy.

Purpose of the Study:

• To review current treatment strategies for follicular lymphoma.
• To identify optimal therapeutic combinations and maintenance approaches.
• To highlight the unmet need in managing high-risk FL patients experiencing early progression.

Main Methods:

• Systematic review of clinical trial data and treatment guidelines for follicular lymphoma.
• Analysis of survival outcomes based on treatment modalities and patient subgroups.
• Evaluation of prognostic factors, including early progression after first-line therapy.

Main Results:

• For advanced-stage FL with low tumor burden, monitoring or single-agent rituximab is appropriate.
• Combining rituximab with chemotherapy (CHOP or bendamustine) improves survival in high tumor burden advanced FL.
• Rituximab maintenance therapy after induction prolongs progression-free survival (PFS).

Conclusions:

• Treatment decisions for FL should be individualized based on stage and tumor burden.
• Chemoimmunotherapy with rituximab, followed by maintenance, is effective for high tumor burden disease.
• Early progression within 24 months identifies a high-risk group requiring novel therapeutic strategies.